A61K 47/6811
The drug being a protein or peptide
Official title: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
A61K47/6811 (The drug being a protein or peptide) appears on 1,994 US grants and 3,280 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,994
- Published applications
- 3,280
- Assignees
- 1,120
- Inventors
- 5,325
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 2 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 6 | 0 |
| 1983 | 5 | 0 |
| 1984 | 3 | 0 |
| 1985 | 2 | 0 |
| 1986 | 4 | 0 |
| 1987 | 8 | 0 |
| 1988 | 7 | 0 |
| 1989 | 7 | 0 |
| 1990 | 16 | 0 |
| 1991 | 7 | 0 |
| 1992 | 16 | 0 |
| 1993 | 11 | 0 |
| 1994 | 11 | 0 |
| 1995 | 6 | 0 |
| 1996 | 13 | 0 |
| 1997 | 26 | 0 |
| 1998 | 39 | 0 |
| 1999 | 29 | 0 |
| 2000 | 26 | 0 |
| 2001 | 20 | 6 |
| 2002 | 29 | 34 |
| 2003 | 23 | 68 |
| 2004 | 18 | 54 |
| 2005 | 12 | 53 |
| 2006 | 28 | 61 |
| 2007 | 18 | 51 |
| 2008 | 23 | 48 |
| 2009 | 38 | 79 |
| 2010 | 47 | 80 |
| 2011 | 36 | 86 |
| 2012 | 53 | 93 |
| 2013 | 51 | 102 |
| 2014 | 67 | 136 |
| 2015 | 78 | 141 |
| 2016 | 97 | 198 |
| 2017 | 120 | 184 |
| 2018 | 111 | 213 |
| 2019 | 123 | 191 |
| 2020 | 121 | 207 |
| 2021 | 124 | 188 |
| 2022 | 112 | 209 |
| 2023 | 117 | 278 |
| 2024 | 104 | 217 |
| 2025 | 111 | 157 |
| 2026 | 68 | 146 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Disruption of CD28-sialoside ligand complexes to enhance T cell activation6 Oct 2026US 12,752,014 B2The Scripps Research Institute
- CD38 antibody drug conjugate15 Sep 2026US 12,734,209 B2Ogory, Inc.
- Use of trigonal agonist having activities to all of glucagon, GLP-1, and GIP receptors in treatment of sequelae following respiratory infectious diseases15 Sep 2026US 12,734,218 B2Hanmi Pharm. Co., Ltd.
- Compositions for targeting muscle cells and uses thereof1 Sep 2026US 12,721,902 B2Cavalry Biosciences, Inc.
- Processes for preparing conjugates of the IL-2 protein1 Sep 2026US 12,723,058 B2Merck Sharp & Dohme Corp.
- Prefusion-stabilized human parainfluenza virus 3 f proteins8 Oct 2026US 2026/0306613 A1Board of Regents, The University of Texas System
- Fap-targeted antibody-drug conjugates8 Oct 2026US 2026/0306653 A1Oncomatryx Biopharma, S.L.
- Antibody targeting dll3 and use of antibody8 Oct 2026US 2026/0308240 A1Neukio Biotherapeutics (Shanghai) Co., Ltd.
- Anti-psma antibodies and uses thereof8 Oct 2026US 2026/0308273 A1Bristol-Myers Squibb Company
- Anti-cmet antibody1 Oct 2026US 2026/0297202 A1Pierre Fabre Medicament
Most cited
By later US patents
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Therapeutic inhibitor of vascular smooth muscle cells562US 5,733,925 ANeoRx Corporation · 1998
- Solubilization of proteins for pharmaceutical compositions using polymer conjugation538US 4,766,106 ACetus Corporation · 1988
- Monomethylvaline compounds capable of conjugation to ligands486US 7,498,298 B2Seattle Genetics, Inc. · 2009
- Cysteine engineered antibodies and conjugates485US 7,521,541 B2Genetech, Inc. · 2009